Phase 1 × Terminated × Lymphoma, Large-Cell, Anaplastic × Clear all A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1 Terminated
3 enrolled
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Phase 1 Terminated
10 enrolled
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1 Terminated
30 enrolled
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
Phase 1 Terminated
6 enrolled
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Phase 1 Terminated
44 enrolled
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Terminated
129 enrolled
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Terminated
22 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Terminated
40 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Phase 1 Terminated
4 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Phase 1 Terminated